Alzheimer’s disease (AD) has a global impact, underscoring the urgency of early and precise diagnosis for effective management. Recent strides in biomarker research hold promise for detecting and monitoring AD at earlier stages. Traditionally, diagnosing AD requires invasive and costly methods like cerebrospinal fluid (CSF) analysis and positron emission tomography (PET). However, the advent of blood-based biomarkers offers the potential for a more accessible and scalable approach in detecting AD pathology. Among these, p-Tau 217, a specific isoform of tau protein phosphorylated at the threonine 217 residue, has emerged as an important biomarker associated with AD. Download our publication brief to learn more.
Share this page